|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 30, 2016 ) Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver cancer, accounting for approximately 85% of liver cancer cases. The prognosis of HCC is dependent on the stage of the disease at diagnosis. However, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.
Highlights
Key Questions Answered
- Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC and has dominated the HCC market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) since its launch.
- The current late and early stage pipeline is very strong and diverse. Which drug will have the biggest impact on the market? What strategies are developers undertaking to overcome the high risk of clinical trial failure?
- Nexavar will lose patent protection within the forecast period. How will this impact the HCC market and will new market entries be able to stabilize the HCC market?
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=676699
Key Findings
- The main driver of growth in the HCC market is the expected launch of second-line treatments for patients with advanced HCC. The market growth will be further supported by an increase in HCC incidence numbers due to a growing aging population as well as market-specific increase in risk factors.
- The biggest barrier for HCC is the patent expiry of Nexavar and expected introduction of generic sorafenib in the 7MM. The effect of this will be strongest in the US where it will have the largest impact on the HCC market. Further patent expiries will also have a negative impact on the HCC market.
- The largest unmet needs in HCC are more treatment options for patients with advanced HCC. First line as well as second line and beyond treatments are urgently needed to improve the treatability of these patients.
Scope
- Overview of HCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HCC market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the HCC therapeutics market.
- Pipeline analysis: focus on the late-stage pipeline HCC drugs discussing emerging trends as well as overview of earlier phase drugs.
- Analysis of the current and future market competition in the global HCC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global HCC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global HCC therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Browse Detail Report With TOC @ http://www.researchmoz.us/opportunityanalyzer-hepatocellular-carcinoma-opportunity-analysis-and-forecasts-to-2024-report.html
Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 HBV Infection 24
3.1.3 HCV Infection 24
3.2 Surveillance of HCC 25
3.3 Alpha-Fetoprotein and other Biomarkers 27
3.4 Pathophysiology 28
3.5 Clinical Staging and Treatment Guidelines 29
3.6 Prognosis and Progression 33
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 37
4.3.1 Incidence 37
4.3.2 Relative Survival 38
4.3.3 Stage at Diagnosis 40
4.4 Forecast Methodology 41
4.4.1 Sources Used 46
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods 50
4.5 Epidemiological Forecast of HCC (2014-2024) 53
4.5.1 Diagnosed Incident Cases of HCC 53
4.5.2 Age-Specific Diagnosed Incident Cases of HCC 55
4.5.3 Sex-Specific Diagnosed Incident Cases of HCC 56
4.5.4 Age-Standardized Diagnosed Incidence of HCC 58
4.5.5 Diagnosed Incident Cases of HCC by BCLC Stages 59
4.5.6 Diagnosed Incident Cases of HCC with HBV and HCV Comorbidities 61
4.5.7 Five-Year Diagnosed Prevalent Cases of HCC 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 66
4.6.3 Strengths of the Analysis 67
5 Current Treatment Options 68
5.1 Overview 68
5.2 Product Profiles - Major Brands 70
5.2.1 Nexavar (sorafenib) 70
5.3 Therapy Approaches 75
5.3.1 Early-Stage HCC Treatment 75
5.3.2 Intermediate and Advanced-Stage HCC Treatment 80
5.4 Other Treatments 85
5.4.1 Adjunctive Therapy and Treatment of Underlying Diseases 85
5.4.2 Systemic Chemotherapy 85
5.4.3 Radiation Therapy 86
6 Unmet Needs Assessment and Opportunity Analysis 87
6.1 Overview 87
6.2 Unmet Needs Analysis 87
6.2.1 Improved Treatability of Late-Stage HCC (First and Second Line) 87
6.2.2 Better Prognostic Biomarkers 89
6.2.3 Safe and Efficacious Adjuvant and Neoadjuvant Therapies 91
6.2.4 Better HCC Surveillance and Prophylactic Treatments 94
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=676699
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
